focus -WSS

focus

author：entertainment 2025-08-19 18:02:43 - browse：13787

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： How Long Island became the ‘eugenics capital of the world’

Wikipedia

focus

WSS

How redistricting in 6 states could affect who controls Congress

Drinking water from half of US faucets contains PFAS: Study

Winners, losers from Medicare’s list of drugs subject to price talks

Medicare explains how it will choose drugs for negotiation

Departing Stanford president retracts two papers

Submersible on Titanic tour reported missing off Newfoundland with 5 people aboard

hotspot

focus

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

AstraZeneca bets AAV gene therapy will still deliver the goods

Cancer drug shortages should be causing more outrage

Radiation, mainstay of cancer treatment, begins a fade

23andMe had bad news about my health. I wish a person had delivered it

FDA approves Leqembi, a milestone in Alzheimer’s treatment

What does generative AI mean for health care? We asked experts

UPS workers' union leader explains what's at stake as strike edges closer

Dobbs anniversary: the lost opportunity of abortion as health care

Radiation, mainstay of cancer treatment, begins a fade

knowledge

AstraZeneca bets AAV gene therapy will still deliver the goods

FDA approves Leqembi, a milestone in Alzheimer’s treatment

How a symptom of dementia informs our understanding of creativity

Medicare explains how it will choose drugs for negotiation

As pharma fights Medicare drug negotiation, hospitals, docs silent

NYU Langone launches private ChatGPT for its health care data

entertainment

Wikipedia

focus

Wikipedia